SlidesetHIVViral Hepatitis and Liver DiseaseProfessor David Cooper Tribute Eulogy- Praphan Phanuphak, MD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseIP and regulatory barriers to access ART and drugs for co-infections in LMICs- Leena MenghaneyView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseTreatment regimens for the public health approach – do we need to change?- Nicholas Paton, MD, FRCPView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseDavid Cooper Memorial Lecture: Current effort to control the epidemic in the region- Nittaya Phanuphak, MD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseDerivation of population mixing patterns from virus sequence data and their impacts on the modelling of HIV epidemics in MSM- Ngai Sze WongView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseTransmitted drug resistance and impact on long-term clinical outcomes in the VMVN clinical trial in Hanoi, Vietnam- Thuy LeView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseChemsex: prevalence, characteristics and associated risk profiles of men who have sex with men in South Australia: a cross-sectional cohort study- Carole KhawView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseChallenges in the management of advanced HIV disease from the clinical perspective- Linghua Li, MD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseCurrent gaps between policy and practice in the Asia Pacific region- Nagalingeswaran Kumarasamy, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseSocial media to increase HIV testing uptake in China- Weiming Tang, PhD, MS, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseasePublic health approach to reduce the burden of advanced HIV disease- Polin Chan, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseSystematic review of social media HIV interventions- Bolin Cao, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseHuman papillomavirus prevalence and behavioral risk factors among HIV-Infected men in central Taiwan- Yuan-Ti LeeView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseDrivers for mental health issues among young and old HIVinfected individuals and opportunities for intervention- Reena RajasuriarView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseOutcome of HCV treatment by direct acting antiretroviral (DAAs) among HCV/HIV co-infections in Vietnam- Thu NguyenView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseIdentifying MSM-competent physicians in China: A national online cross-sectional survey among physicians who see male HIV/STD patients- Peipei ZhaoView Slideset
SlidesetHIVViral Hepatitis and Liver DiseasePre-exposure prophylaxis (PrEP) service in a South East Asian university hospital – one year experience- Dariusz Piotr OlszynaView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseTreatment for anorectal Chlamydia trachomatis infection with azithromycin 1g single dose in mem who have sex with men w/o HIV infection- Daisuke MizushimaView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseReducing condomless sex among Chinese Men Who Have Sex with Men through repeated exposure to online videos: results from an online cohort study- Wenting HuangView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseThe pattern of risk compensation in MSM enrolled in a pilot PrEP project- Tsz Ho KwanView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseVoices of the hidden: Implementation of the people living with HIV stigma index in Taiwan- Yi-Chi ChiuView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseCost-effectiveness of Dolutegravir in HIV-1 treatment-naïve patients in China- Yogesh PunekarView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseDTG versus LPV/r in second line (DAWNING): outcomes by WHO-recommended NRTI backbone- Yinzhong ShenView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAssessing the efficacy of Lopinavir /ritonavir based preferred and alternative second-line regimens on HIV-infected patients : a meta-analysis as a key evidence support for WHO recommendations- Yaokai ChenView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseRoutine versus targeted viral load strategy among patients starting ART in Hanoi, Vietnam- Todd PollackView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseReplicating the success: Using an HIV model of peer driven intervention (PDI+) to increase TB new case detection in Cambodia- Kolab ChhimView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseOptimal timing of antiretroviral therapy for HIV-infected patients with cryptococcal meningitis: A systematic review and meta-analysis- Yaokai ChenView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseImproving tolerability by optimizing ART- Kiat Ruxrungtham, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseSocial media platforms for LGBT inclusion- Laurindo GarciaView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAddressing long-term complications to improve health outcomes in HIV- Reena Rajasuriar, MPharm, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseImpact of initiation of combination antiretroviral therapy according to the WHO recommendations on the survival of HIV-positive patients in Taiwan- Wang-Da LiuView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseFeasibility and outcome of rapid initiation of antiretroviral treatment among newly-diagnosed HIV-positive patients at a tertiary center in Taiwan- Yi-Chia HuangView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseChanges in creatinine and estimated glomerular filtration rate during the first 12-month period of pre-exposure prophylaxis among PrEP-30 clients at the Thai Red Cross anonymous clinic- Piyanuch TuntikulView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseRenal and liver function changes among post-exposure prophylaxis clients at the Thai Red Cross Anonymous Clinic in Bangkok- Samanan ThongyoiView Slideset
SlidesetHIVViral Hepatitis and Liver DiseasePro debater: IPT should be implemented for all HIV patients in the Asia-Pacific- Mark Boyd, BA, BM, BS, DCTH&H, MHID, MD, FRACPView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseCon debater: IPT should be implemented for all HIV patientsin the Asia-Pacific- Thuy Le, MD, DPhilView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseKPLHS for same-day ART and differentiated service delivery in Thailand- Chamrong PhaengnongyangView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseSustainability of KPLHS through capacity building platform- Rangsima Airawanwat, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseWhy we need KPLHS to end AIDS in the Asia Pacific- Michael Cassell, PhD, MEM, MAView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseBroadly neutralizing antibodies for treatment and prevention of HIV-1- Daniel Kuritzkes, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseIntroduction to immunology - What clinicians need to know- Paul Cameron, BMedSci, MBBS, PhD, FRACP, FRCPAView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseHep C: How we are going to get to hep C elimination from a clinician’s perspective- Gail Matthews, MBCHB, MRCP (UK), FRACP, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseHep C: Country experience with elimination efforts- Vithurneat Hang, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseResearch methodology- Matthew Law, BA (Hons), MSc, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseGetting involved in clinical research: from clinical trials to sub-studies- Nicholas Paton, MD, FRCPView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseHow to do a systematic review- Matthew Law, BA (Hons), MSc, PhD & Joseph Tucker, MD, PhD, AMView Slideset
